No Data
No Data
No Data
No Data
No Data
Is Now The Time To Look At Buying Jinxin Fertility Group Limited (HKG:1951)?
Jinxin Fertility Group Limited (HKG:1951), is not the largest company out there, but it saw significant share price movement during recent months on the SEHK, rising to highs of HK$2.84 and falli
Simply Wall StApr 16 18:25 ET
China Post Securities: Endogenous growth is steady, and the Hong Kong stock healthcare services sector's valuation is highly attractive
Judging from the overall performance of medical service targets in Hong Kong stocks, with the exception of ICL's high revenue base in the early COVID-19 period, where dental revenue was affected by dental implant collection, most of the revenue from other medical service targets increased relatively well.
Zhitong FinanceApr 12 03:07 ET
Changes in Hong Kong stocks | Jinxin Reproduction (01951) rose by more than 6%, and assisted reproduction was included in health insurance companies in many places to expand the assisted reproduction market in Southeast Asia
Jinxin Reproduction (01951) rose more than 6%. As of press release, it rose 6.17% to HK$2.58, with a turnover of HK$29.36,500.
Zhitong FinanceApr 8 22:29 ET
[Hong Kong Stock Connect] Jinxin Reproduction (01951) rose 5.76%, Citi says its valuation is still attractive
Jinwu Financial News | Jinxin Reproduction (01951) stock price fluctuated and rose in early trading. As of press release, it had risen 5.76% to HK$2.57. According to the news, on April 1, Jinxin Reproductive Medical Group Co., Ltd. announced the signing of an equity investment agreement with PT Morula Indonesia. Jinxin Fertility said that after the investment is completed, Jinxin Fertility will become Morula's largest strategic investor. At the same time, the two sides will reach strategic cooperation, achieve resource integration, and work together to develop the assisted reproduction industry market in Indonesia and Southeast Asia. Citi released a research report saying that it will maintain Jinxin Reproduction's “buy” rating and consider
金吾財訊Apr 8 22:23 ET
Jinxin Reproduction (01951.HK) and Indonesia's Morula reached an equity strategic investment cooperation to expand the assisted reproduction market in Southeast Asia
On April 1, 2024, Jinxin Reproductive Medicine Group Co., Ltd. (01951.HK) announced the signing of an equity investment agreement with Indonesia's PT Morula Indonesia (“Morula”). After the investment is completed, Jinxin Fertility will become Morula's largest strategic investor. At the same time, the two sides will reach strategic cooperation, achieve resource integration, and jointly explore the assisted reproduction industry market in Indonesia and Southeast Asia. The population of Southeast Asia is huge and continues to grow. At the same time, with economic development, residents' consumption capacity is also increasing, and the assisted reproduction industry has great potential for growth.
Gelonghui FinanceApr 1 11:15 ET
Open Source Securities: Maintaining Jinxin Reproduction's (01951) “Buy” rating, Shenzhen's new hospital is expected to be put into operation
Open Source Securities estimates that Jinxin Reproduction (01951)'s net profit for 2024-26 will be $3.87/46,538 million yuan.
Zhitong FinanceApr 1 01:54 ET
No Data
No Data